Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease)). حسب Mobina Faqani (22783963)

"…<p>Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease)).…"

Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease). حسب Mobina Faqani (22783963)

"…<p>Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease).…"

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. حسب Peiqi Yin (6533747)

IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1. حسب Iratxe Zuazo-Gaztelu (21071939)

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. حسب Cristina Dolciotti (16317330)

The mean and standard deviation of parameters. حسب Sadaf Sepasgozar Sarkhosh (20436143)

الموضوعات:

Middle cerebral artery mean flow velocity at three time points. حسب Marco Carbonara (11483575)

الموضوعات:

Epilepsy, including probable nodding syndrome (pNS), and pNS prevalence per study county in high- and low-risk sites in South Sudan. حسب Luís-Jorge Amaral (16406704)

الموضوعات:

HFD decreases intermediate-term memory. حسب Tong Yue (6033305)

"…<p>(A) The survival rate of 10d <i>Canton-S</i> fed with ND or HFD was observed for 7 days. There was no significant decline in the survival rate in flies fed with HFD compared with ND (n = 10 vials, containing 20 flies at each time point). …"

Summary of post-treatment disease course measures from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Study selection criteria. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. حسب Filip Stanicic (17808254)

الموضوعات:

Disease course measures after the PTSD treatments. حسب Filip Stanicic (17808254)

الموضوعات:

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from off-label medications clinical trials. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

PRISMA flow chart. حسب Filip Stanicic (17808254)

الموضوعات: